Intervirew with Dimerix (ASX:DXB) CEO Dr. Nina Webster
We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB) about the important Phase 3 study of DMX-200 in a rare kidney disease called Focal Segmental Glomerulosclerosis. This study reads out its first interim analysis in mid-March 2024. A second analysis later in the trial can potentially open up accelerated approval of the drug. The company recently signed a very significant deal!
Check out the Initiating Research Report on Dimerix by Pitt Street Research HERE!
What are the Best ASX Stocks to invest in right now?
Check our ASX buy/sell tips
